@ShahidNShah
Digital health companies should stay away from FDA in 2021
As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.
Continue reading at mobihealthnews.com
Make faster decisions with community advice
Next Article
-
Our Favourite Digital Health Articles Of 2020
Yes, it’s THAT time of the year and it’s always good to look back at the year – even to this one. For it’s easy to say 2020 was disastrous, but there were many aspects that bring hope for the future …
Posted Dec 22, 2020digital health